Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (“Neuroprotection”)

Neurotherapeutics

Volumn 12, Issue 2, 2015, Pages 449-454

  Wiendl, Heinz ^a   Elger, Christian ^b   Förstl, Hans ^c   Hartung, Hans Peter ^d   Oertel, Wolfgang ^e   Reichmann, Heinz ^f   Schwab, Stefan ^g  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Alzheimer s disease; multiple sclerosis; neurodegeneration; Neuroprotection; Parkinson s disease; stroke

Indexed keywords

NEUROPROTECTIVE AGENT;

ANIMAL; HUMAN; NEURODEGENERATIVE DISEASES; NEUROPROTECTION; PHYSIOLOGY; STANDARDS;

ANIMALS; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTION; NEUROPROTECTIVE AGENTS;

EID: 84937975456     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-015-0348-8     Document Type: Article

References (22)

1. Zipp F, Gold R, Wiendl H. Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies? JAMA Neurol 2013;70:1569-1574.
2. Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010;33:140-152.
3. Casson RJ, Chidlow G, Ebneter A, Wood JP, Crowston J, Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin Exp Ophthalmol 2012;40:350-357.
4. Seidl SE, Potashkin JA. The promise of neuroprotective agents in Parkinson's disease. Front Neurol 2011;2:68.
5. Dirnagl U. Modeling immunity and inflammation in stroke: can mice be trusted? Stroke 2014;45:e177-e178.
6. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
7. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
8. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14:795-806.
9. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014;31:1134-1154.
10. Feinstein A, Freeman J, Lo AC. Progressive multiple sclerosis 2 Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol 2015;14:194-207.
11. Ontaneda D, Fox RJ, Chataway J. Progressive multiple sclerosis 3 Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol 2015;14:208-223.
12. Mahad DH, Trapp BD, Lassmann H. Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol 2015;14:183-193.
13. Cedarbaum JM, Stephenson D, Rudick R, et al. Commonalities and challenges in the development of clinical trial measures in neurology. Neurotherapeutics 2015;12:151-169.
14. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183-200.
15. Meuth SG, Bittner S, Ulzheimer JC, Kleinschnitz C, Kieseier BC, Wiendl H. Therapeutic approaches to multiple sclerosis an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies. BioDrugs 2010;24:317-330.
16. Chow SC. Adaptive clinical trial design. Annu Rev Med 2014;65:405-415.
17. Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-767.
18. Wiendl H. Fingolimod: a new drug with a new mechanism of action. Basic Clin Pharmacol 2011;109:4-5.
19. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373-382.
20. Novartis. Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) Media release. Available from: http://www.novartis.com/newsroom/media-releases/en/2014/1875463.shtml. Accessed 13 Feb 2015.
21. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278-286.
22. Novartis. Novartis announces collaboration with Banner Alzheimer's Institute on a pioneering prevention study for Alzheimer's Disease. Available from: http://hugin.info/134323/R/1824651/632000.pdf. Accessed 13 Feb 2015.